Acute Lymphoid leukemia in Albania, retrospective study􀀀

by, Genta Smaja, A. Cili, T. Caja, P. Polluqi, A. Perolla, E. Calliku, and A. Ivanaj

Abstract

The incidence of acute lymphoid leukemia is increasing worldwide. In our country, there are no reports clearly describing the incidence of this malignancy or the reports are incomplete. Aim: In this study, our main aim is to investigate the number of the new cases of the disease in adults during the period of time 2013-2017 in Albania. We can say that by investigating the number of the new cases in QSUT during this period, we have investigated the number of new cases in Albania because QSUT is the biggest hospital center in Albania. Materials and method: This is a cohort retrospective study and we reviewed all the data from patients’records and hospital register, protecting the patient confidenciality in accordance with Helsinki declaration. We have analyzed the patient based on their demographic, diagnostic and therapeutic characteristics, followed by a statistical analysis to predict the disease’s prognosis using SPSS and MedCALC software. Conclusions: We came to a final result that the incidence of acute lymphoblastic leukemia in adults in our country is about 0.6-1/100000 per year. Male to female ratio is 1.4/1. The age-group with the biggest number of new cases was 60-69 years old. Most of the new cases come from big cities and urban areas. The mean age was about 48.7 years old. Total DFS is 16.3 months. The most common treatment regimen used in our country is Rossi-Ferrini, followed by Hyper CVAD, CALBG and AEIOP 95’. We also tried to find a statistical difference between the regimens used, but there was no significant difference, probably due to the small number of the sample we have studied. We came to another conlusion that there is a significant statistical difference between age differences and WBC at presentation and DFS (disease free survival). DFS for age above 60 is 7 months comparing with 10 months for patients under 60 (p=0.09). 24 MEDICUS / No. 2, 2018 25 As for WBC number, DFS is 6 months for WBC>30,000/μL and 12 months for WBC <30,000/μL (p=0.07).Finally we can say that these two factors mentioned above are really important prognostic factors for this malignancy.